The company and its reps need to better communicate this point to the US health authorities otherwise they could lose a large chunk of their customer base over a simple understanding - perhaps CST can purchase a small supplier in the US market - the currency is favourable for US asset purchases by aussie biotech companies - might add a degree of footprint and increase communications in this way.
